eligibility_summary
Adults ≥18 with confirmed B‑cell NHL, R/R after ≥1 line incl anthracycline + anti‑CD20, no prior CD19 CAR‑T, adequate organs, apheresis access, consent, contraception if fertile. Exclude: prior allo‑HSCT, CNS disorders, other malignancy <2 y (except select in situ/skin/superficial bladder), major CV disease or LVEF<50%, active HBV/HCV viremia, HIV, or infection, autoimmune disease/transplant/immunosuppression, uncontrolled DM/HTN, substance abuse, autoimmune organ damage <2 y.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06695013 evaluates adding immunobridging to CAR-T in low‑risk R/R B‑NHL. Core therapy: autologous CD19‑directed CAR‑T cells (gene‑modified T‑cell therapy) that bind CD19 on malignant B cells and mediate cytotoxicity/cytokine release. Bridging (experimental): zanubrutinib (oral, covalent small‑molecule BTK inhibitor) ± focal radiotherapy, control: no bridging. Maintenance (if PR at D28 in either arm): zanubrutinib + tislelizumab (anti‑PD‑1 monoclonal antibody) for 2 years, CR: no maintenance. Targets/pathways: CD19+ B‑cell lymphoma cells (CAR‑T), B‑cell receptor signaling via BTK → NF‑κB/PI3K/MAPK (zanubrutinib), PD‑1 checkpoint on T cells to reverse exhaustion and enhance CAR‑T persistence/function (tislelizumab), radiotherapy induces local DNA damage and antigen release.